One-year acne tolerability of abrocitinib versus upadacitinib in moderate-to-severe atopic dermatitis: an unanchored matching-adjusted indirect comparison
SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s846
DOI: 10.25251/s8yn8r04 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Stephen Weidinger und 10 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Janus kinase inhibitors (JAKi), including abrocitinib and upadacitinib, are effective systemic therapies for moderate-to-severe atopic dermatitis (M2S AD) and have demonstrated superiority to dupilumab. Acne is a notable JAKi class-level adverse event observed across randomized clinical trials (RCTs) and real-world clinical practice. Acne is a burdensome adverse event that can undermine treatment adherence, persistence, and satisfaction in patients with M2S AD. The objective of this study was to provide indirect comparative data for risk of acne with high and low doses of abrocitinib versus upadacitinib over 1 year of treatment.
Methods
Four abrocitinib monotherapy RCTs (JADE MONO 1 [NCT03349060], MONO 2 [NCT03575871], MOA [NCT03915496], and EXTEND [NCT03422822]) and 2 upadacitinib monotherapy RCTs (Measure Up 1 [NCT03569293] and Measure Up 2 [NCT03607422]) were included. Placebo crossover patients who later received abrocitinib/upadacitinib in the long-term extension study JADE EXTEND or long-term extension periods of Measure Up 1/2 were also included. Standard matching-adjusted indirect comparison methods were used for adjustments based on treatment effect modifiers. Odds ratios (OR) for acne with abrocitinib (200 or 100 mg) versus upadacitinib (30 or 15 mg) after up to 1 year of treatment were calculated.
Results
Data from 774 patients treated with abrocitinib (100 mg, n=431; 200 mg, n=343) and 1608 patients treated with upadacitinib (15 mg, n=797; 30 mg, n=811) were included. There was evidence of higher odds of acne with upadacitinib 30 mg versus abrocitinib 200 mg (OR [95% CI], 3.39 [2.14-5.36]; P
Zitieren
APA
Weidinger, S., Bunick, C. G., Irvine, A., Hong, H. C., Thom, H., Orishaba, P., Aceituno, D., Law, E. H., Kurosky, S. K., Koppensteiner, H., & Chen, S. (2026). One-year acne tolerability of abrocitinib versus upadacitinib in moderate-to-severe atopic dermatitis: an unanchored matching-adjusted indirect comparison. SKIN The Journal of Cutaneous Medicine, 10(6), s846. https://doi.org/10.25251/s8yn8r04
Vancouver
Weidinger S, Bunick CG, Irvine A, Hong HC, Thom H, Orishaba P, et al. One-year acne tolerability of abrocitinib versus upadacitinib in moderate-to-severe atopic dermatitis: an unanchored matching-adjusted indirect comparison. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s846. doi:10.25251/s8yn8r04
BibTeX
@article{Weidinger2026,
author = {Weidinger, Stephen and Bunick, Christopher G. and Irvine, Alan and Hong, H. Chih-ho and Thom, Howard and Orishaba, Philip and Aceituno, David and Law, Ernest H. and Kurosky, Samantha K. and Koppensteiner, Herwig and Chen, Simon},
title = {One-year acne tolerability of abrocitinib versus upadacitinib in moderate-to-severe atopic dermatitis: an unanchored matching-adjusted indirect comparison},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {6},
pages = {s846},
doi = {10.25251/s8yn8r04}
}
EUVIMED